- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04304053
Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention (HCQ4COV19)
Treatment of Non-severe Confirmed Cases of COVID-19 and Chemoprophylaxis of Their Contacts as Prevention Strategy: a Cluster Randomized Clinical Trial (PEP CoV-2 Study)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Hydroxychloroquine (HCQ) is a drug that has been extensively used for the prevention of malaria. HCQ showed excellent in vitro results and strong antiviral effects on SARS-CoV-2 infection of primate cells at low concentration. Empirical data for the efficacy of HCQ in hospitalized Covid-19 patients became available after the start of this study; HCQ administration did not result in a significantly higher PCR negative conversion in a RCT including 150 patients and there was no reduction in the risk of death/intubation in two large observational studies.
Study 1 -We investigated the efficacy and safety of HCQ to prevent secondary SARS-CoV-2 infection and Covid-19 disease in contacts exposed to a PCR-positive Covid-19 case during.
Study 2- We also conducted a study to test the hypothesis that HCQ treatment would be more efficacious than no-treatment for patients with mild Covid-19.
Initially, the protocol included the use of combined treatment with a HIV protease inhibidor (cobicistat-boosted darunavir) for cases (study 2), but it was adapted to HCQ alone after the recommendation of the pharmaceutical company not to use DRVc for the treatment of Covid-19 due to lack of activity in-vitro.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Barcelona, Spain
- Departament de Salut
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Study 1:
Inclusion Criteria for a contact:
- Asymptomatic individuals exposed to a PCR confirmed COVID19 case within 7 days as either a healthcare worker or household contact
- Aged ≥18 years male or female;
- In women of childbearing potential, negative pregnancy test and commitment to use contraceptive method throughout the study.
- Willing to take study medication;
- Willing to comply with all study procedures;
- Able to provide oral, informed consent and/or assent.
Exclusion Criteria for a contact:
- With known history of cardiac arrhythmia (or QT prolongation syndrome);
- Unable to take drugs by mouth;
- With significantly abnormal liver function (Child Pugh C)
- Need of dialysis treatment, or GFR≤30 mL/min/1.73 m2;
- Participants with psoriasis, myasthenia, haematopoietic and retinal diseases,CNS-related hearing loss or glucose-6-phosphate dehydrogenase deficit;
- Persons already treated with any of the study drugs during the last 30 days;
- Pregnant or lactating women;
- Any contraindications as per the Data Sheet of Hydroxychloroquine.
Study 2:
Inclusion Criteria for a case:
- Patients who meet the requirements of the New Coronavirus Infection Diagnosis (Acute <5 days respiratory infection symptoms, or fever alone, or acute cough alone and positive PCR)
- Aged ≥18 years male or female;
- In women of childbearing potential, negative pregnancy test and commitment to use contraceptive method throughout the study.
- Willing to take study medication
- Willing to comply with all study procedures, including repeat nasal swab at day 3
- Able to provide oral and written informed consent
Exclusion Criteria for a case:
- Hospital admission
- Serious condition meeting one of the following: (1) respiratory distress with respiratory rate >=30 breaths/min; (2) oxygen saturation<=93% on quiet status; (3) Arterial partial pressure of oxygen (PaO2)/oxygen concentration<=300mmHg;
- Critically ill patients meeting one of the following: (1) Experience respiratory failure and need to receive mechanical ventilation; (2) Experience shock; (3) Complicated with other organs failure and need intensive care and therapy in ICU;
- Participants under treatment with medications likely to interfere with experimental drugs
- Unable to take drugs by mouth;
- With significantly abnormal liver function (Child Pugh C)
- Need of dialysis treatment, or GFR≤30 mL/min/1.73 m2;
- Participants with psoriasis, myasthenia, haematopoietic and retinal diseases,CNS-related hearing loss or glucose-6-phosphate dehydrogenase deficit
- Participants with severe neurological and mental illness;
- Pregnant or lactating women;
- Inability to consent and/or comply with study protocol;
- Individuals with known hypersensitivity to the study drugs.
- Persons already treated with any of the study drugs during the last 30 days.
- Any contraindications as per the Data Sheet of Hydroxychloroquine.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: No Intervention- SARS-CoV-2 surveillance
Study 1- Contacts will complete a survey collecting demographic, epidemiological and clinical data and provides a swab for RT-PCR testing at baseline and day 14. Study 2- Index case completes a survey collecting demographic, epidemiological and clinical data and provides a swab for RT-PCR testing at baseline and on days 3 and 7. Isolation of patient and contact tracing as per national guidelines. |
Isolation of patient and contact tracing as per national guidelines.
|
Experimental: Testing, treatment and prophylaxis of SARS-CoV-2
Study 1- Contacts receive Hydroxychloroquine prophylaxis. Contacts will complete a survey collecting demographic, epidemiological and clinical and provides a swab for RT-PCR testing at baseline and day 14. Study 2- Index case receives Hydroxychloroquine. Index case completes a survey collecting demographic, epidemiological and clinical data and provides a swab for RT-PCR testing at baseline and on days 3, and 7. Isolation of patient and contact tracing as per national guidelines. |
Isolation of patient and contact tracing as per national guidelines.
Cases will be offered a therapeutic regimen hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2-7 Contacts will be offered a prophylactic regimen of hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2-7. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Study 1- Clinical and virological outcome in exposed contacts
Time Frame: Up to 14 days after start of treatment
|
Incidence of secondary PCR confirmed symptomatic Covid-19 episodes among contacts after high risk PCR+ exposure
|
Up to 14 days after start of treatment
|
Study 1- Transmission of SARS-CoV-2 in exposed contacts
Time Frame: Up to 14 days after start of treatment
|
Incidence of symptomatically compatible or a PCR-positive result regardless of symptoms
|
Up to 14 days after start of treatment
|
Study 2- Virological outcome in index cases
Time Frame: Up to 7 days after start of treatment
|
Reduction of viral RNA load in nasopharyngeal swabs at days 3, and 7 after treatment start.
|
Up to 7 days after start of treatment
|
Study 2- Clinical outcome in index cases
Time Frame: Up to 28 days after start of treatment
|
Time from randomization to complete resolution of symptoms at an extended 28-days follow-
|
Up to 28 days after start of treatment
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Akhtar S, Das JK, Ismail T, Wahid M, Saeed W, Bhutta ZA. Nutritional perspectives for the prevention and mitigation of COVID-19. Nutr Rev. 2021 Feb 11;79(3):289-300. doi: 10.1093/nutrit/nuaa063.
- Mitja O, Corbacho-Monne M, Ubals M, Alemany A, Suner C, Tebe C, Tobias A, Penafiel J, Ballana E, Perez CA, Admella P, Riera-Marti N, Laporte P, Mitja J, Clua M, Bertran L, Sarquella M, Gavilan S, Ara J, Argimon JM, Cuatrecasas G, Canadas P, Elizalde-Torrent A, Fabregat R, Farre M, Forcada A, Flores-Mateo G, Lopez C, Muntada E, Nadal N, Narejos S, Nieto A, Prat N, Puig J, Quinones C, Ramirez-Viaplana F, Reyes-Uruena J, Riveira-Munoz E, Ruiz L, Sanz S, Sentis A, Sierra A, Velasco C, Vivanco-Hidalgo RM, Zamora J, Casabona J, Vall-Mayans M, Gonzalez-Beiras C, Clotet B; BCN-PEP-CoV2 Research Group. A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19. N Engl J Med. 2021 Feb 4;384(5):417-427. doi: 10.1056/NEJMoa2021801. Epub 2020 Nov 24.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HCQ4COV19
- 2020-001031-27 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on Standard Public Health measures
-
Istituto Auxologico ItalianoRecruiting
-
University of ChileNot yet recruitingCovid19 | Death | Infectious Disease | SARS-CoV InfectionChile
-
NGO Via LibreUniversity of WashingtonCompleted
-
Institut BergoniéCompleted
-
Universidad de AlmeriaMinisterio de Ciencia e Innovación, SpainCompletedChronic DiseaseSpain
-
The HIV Netherlands Australia Thailand Research...Mahidol University; Sanpatong Hospital; Chiangrai Prachanukroh Hospital; Bamrasnaradura...Completed
-
The HIV Netherlands Australia Thailand Research...Sanpatong Hospital; Bamrasnaradura Infectious Diseases InstituteCompleted
-
Institut de Recherche pour le DeveloppementInstitut de Recherche en Sciences de la Sante, Burkina Faso; Expertise France; Institut Pierre RichetRecruitingMalariaBurkina Faso, Côte D'Ivoire
-
Meso Scale Diagnostics, LLC.Centers for Disease Control and PreventionTerminated
-
International Centre for Diarrhoeal Disease Research...University of California, Berkeley; University of Maryland; Harvard UniversityCompletedDevelop a New Group Version of the Becker-DeGroot-Marsckek (BDM) Auction to Measure Willingness to Pay of Compound Members for Shared Hardware. | Develop a New Survey Instrument to Measure Behavioural Determinants of Hand Washing and Water Treatment Like Disgust and Shame or Social... and other conditionsBangladesh